好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Digital Histological Measurements Show a Range of Values Within Traditional Pathological Metrics of AD-related Tau Pathology
Aging, Dementia, and Behavioral Neurology
P3 - Poster Session 3 (5:30 PM-6:30 PM)
7-002
To examine spectrum of neocortical tau burden using digital histological methods in Alzheimer’s disease (AD) and Lewy Body Disease (dementia with Lewy bodies and Parkinson’s disease) with AD co-pathology (LBD+AD) with high Braak tau stages.
Neuropathological assessment remains gold-standard for diagnosing and staging neurodegenerative diseases. Digital histological assessment may capture a spectrum of pathological burden not easily demonstrated by traditional methods.
Cases from UC-San Diego (UCSD) and University of Pennsylvania (UPenn) with AD (UCSD:15, UPenn:33) and LBD+AD (UCSD:7, UPenn:10) with Braak tau stages V and VI (B3) had middle frontal cortex (MFC), superior temporal cortex (STC), and angular gyrus (ANG) immunohistochemically stained for pathological tau inclusions (AT8) and whole-slide images analyzed for tau %area occupied (tau%AO) using QuPath image analysis software. Natural-log tau%AO values were compared between ordinal severity scores (0-3), Braak stages, and between AD and LBD+AD in each region using ANOVA and t-tests.
In both cohorts, here were significant increases in tau%AO across blinded regional ordinal severity scores (UCSD F=28.4, p<0.001, UPenn F=236, p<0.001). All regions had higher tau%AO in Braak VI cases than Braak V in the UCSD cohort (p<0.02). The STC harbored the highest tau%AO values in AD and LBD+AD. AD had higher tau%AO than LBD+AD in every region (MFC, STC, ANG, neocortical average: t=2.2-4.3, p<0.03).
Digital histological measurements recapitulate aspects of known patterns of AD-related tau pathology but reveal a range of pathological burden within current grading and staging systems. These methods may have relevance for ongoing biomarker development and modeling disease using human histology.
Authors/Disclosures
David G. Coughlin, MD (University of California San Diego)
PRESENTER 		Dr. Coughlin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for M3 Global Research. The institution of Dr. Coughlin has received research support from 好色先生. The institution of Dr. Coughlin has received research support from NIA. The institution of Dr. Coughlin has received research support from NINDS.
Yongya Kim No disclosure on file
Sanaz Arezoumandan, MD (University of Pennsylvania) Sanaz Arezoumandan, MD has nothing to disclose.
Claire S. Peterson Ms. Peterson has nothing to disclose.
Anne E. Hiniker, MD (University of California, San Francisco) Dr. Hiniker has nothing to disclose.
Larry Hansen No disclosure on file
Robert A. Rissman, PhD (University of California, San Diego) Dr. Rissman has nothing to disclose.
No disclosure on file
No disclosure on file
David Irwin, MD (University of Pennsylvania) The institution of Dr. Irwin has received research support from NIH. The institution of Dr. Irwin has received research support from Prevail. The institution of Dr. Irwin has received research support from Passage Bio. The institution of Dr. Irwin has received research support from Alector. The institution of Dr. Irwin has received research support from Transposon. The institution of Dr. Irwin has received research support from Denali. The institution of Dr. Irwin has received research support from Cervo Med.